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Abstract
Myeloma cast nephropathy (MCN) is a common cause of severe renal impairment in multiple myeloma (MM). The
level of free light chain (FLC) that causes MCN varies substantially and there is uncertainty about the threshold level
that should be used to inform clinical practice. In a multicentre cohort study of 103 patients with a diagnosis of MM
and biopsy-conﬁrmed MCN made between 2002–2014, we report prospectively measured levels of serum FLC at
diagnosis obtained using a single nephelometric assay (Freelite®) and we explore the relationship between serum FLC
level at diagnosis with renal outcome and patient survival. Using a landmark approach, overall survival (OS) was
compared between patients who achieved independence from dialysis compared to those who remained dialysis
dependent at 3-month, 6-month, 9-month, and 12-month time points. The median serum FLC level at diagnosis was
7531 mg/L (range 107–114600). Serum creatinine was 535 μmol/L (range 168–2993) and eGFR 7 ml/min/1.73 m2
(range 1–34). Six patients (5.8%) had an FLC level <1500 mg/L, which is the International Myeloma Working Group
threshold for MCN and two patients were below the International Kidney and Monoclonal Gammopathy working
group threshold of 500 mg/L; one was hypercalcaemic, and one had high-normal serum calcium level and had
received a non-steroidal anti-inﬂammatory agent. Sixty-nine (67%) patients required haemodialysis treatment of whom
36 (52.1%) recovered independent renal function. Sixty-six (64%) patients died with a median OS of 2.5 years (95% CI
1.8–3.3). A landmark analysis revealed that independence from dialysis was associated with improved survival at 3-
months (P= 0.003), 6-months (P= 0.035) and 9-months (P= 0.014); there was no survival beneﬁt observed beyond
12 months (P= 0.146). Serum FLC level at diagnosis was neither associated with renal function recovery nor with OS.
This is the largest reported cohort of patients with biopsy-conﬁrmed MCN and prospectively measured serum FLC
levels. These results indicate that a serum monoclonal FLC > 500 mg/L should be considered the threshold level
associated with the development of MCN.
Introduction
Renal function impairment (RI) is reported in up to 50%
of patients with multiple myeloma (MM) at presenta-
tion1–6. Severe RI as deﬁned by an estimated glomerular
ﬁltration rate (eGFR) <30ml/min/1.73 m2 is present in up
to 20% of patients with MM at diagnosis7, which
approximates to the level of renal dysfunction deﬁned by
the renal component of the end-organ damage (hyper-
calcemia [C], renal failure [R], anaemia [A], or bone
lesions [B], herein referred to as CRAB) classiﬁcation
system8. The predominant cause for severe RI is the
pathognomonic distal tubular lesion, myeloma cast
nephropathy (MCN), which is a direct consequence of the
secreted monoclonal immunoglobulin (Ig) free light chain
(FLC)9. The level of pathogenic serum FLC that causes
MCN varies substantially and there is uncertainty about
the threshold level that should be used to inform clinical
practice10.
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A paradigm shift in the management of patients with
MM has been the development of the serum FLC assay11,
which is now the test recommended by the International
Myeloma Working Group (IMWG) for the screening of
patients with a suspected paraproteinemia12. The IMWG
recently revised the criteria for the diagnosis of MM in
cases without CRAB features to include an involved to
uninvolved serum FLC ratio >100 in association with an
involved FLC level above 100 mg/L, clonal bone marrow
plasma cells ≥60 percent, or more than one focal bone
lesion (>5 mm) identiﬁed using magnetic resonance
imaging13.
The serum FLC assay is used in patients with unex-
plained acute kidney injury (AKI) to screen for potential
MCN. However, the range of FLC at which MCN can
occur is uncertain. The IMWG associated RI as a con-
sequence of MCN to a serum FLC level above 1500 mg/
L13, whereas the International Kidney and Monoclonal
Gammopathy (IKMG) Research Group proposed a
serum FLC level above 500 mg/L14. We recently ana-
lysed the Myeloma IX study and found that an FLC level
above 800 mg/L had the highest sensitivity and speci-
ﬁcity for severe RI deﬁned by an estimated glomerular
ﬁltration rate (eGFR) <30 ml/min/1.73 m2 at diag-
nosis15. However that study did not include patients
who required dialysis and information on renal histol-
ogy was not available. Additionally, it is also uncertain if
the level of FLC in serum at presentation is an inde-
pendent determinant of outcome in patients with AKI
and MCN.
Therefore, the aim of this study was to primarily report
the range of FLC levels in serum in patients with newly
diagnosed MM who had AKI from renal biopsy-
conﬁrmed MCN. Additionally, we also report renal out-
comes for those on dialysis and overall survival (OS) for
the entire cohort.
Patient and methods
This was a multicentre study of newly diagnosed
patients with MM and with biopsy-conﬁrmed MCN
between 2002 and 2014. Patients had presented at three
tertiary centres: University Hospital Birmingham NHS
Foundation Trust (UHB), Birmingham, UK; Mayo Clinic,
Rochester, Minnesota, USA and; University of Alabama at
Birmingham (UAB), Birmingham, Alabama, USA. We
evaluated prospectively measured levels of involved FLC
in serum using a single nephelometric assay (Freelite®,
The Binding Site, Birmingham, UK). Informed consent
was obtained from all patients. Approval for conduct of
this study was obtained from the local ethics committee
or the Institutional Review Board from the three centres
in accordance with the Declaration of Helsinki.
Figure 1 is a CONSORT diagram showing the char-
acteristics of patients included in the study. Inclusion
criteria comprised all patients with a new diagnosis of
MM and biopsy proven MCN. Patients that were exclu-
ded from analysis comprised: (a) those with relapsing/
remitting MM; (b) those known to have chronic kidney
disease (CKD); (c) renal transplant recipients; (d) those
with a histological diagnosis of MCN and other
Fig. 1 CONSORT diagram showing patients included in study. UHB University Hospital Birmingham, FLC free light chain, MCN myeloma cast
nephropathy, MGRS monoclonal gammopathy of renal signiﬁcance.
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paraproteinemia e.g. amyloidosis, renal monoclonal
immunoglobulin deposition diseases, or any other
monoclonal gammopathy of renal signiﬁcance (MGRS);
and (e) patients in whom serum FLC levels were mea-
sured after commencement of anti-myeloma therapy.
Variables included in the analysis were: patient age at
diagnosis, gender, ethnicity, date of presentation with RI,
Modiﬁcation of Diet in Renal Disease study equation
(MDRD) eGFR (ml/min/1.73 m2), corrected serum cal-
cium, haemoglobin, paraprotein and FLC type, serum FLC
level at presentation, date of renal biopsy, days from
presentation to renal biopsy, days from presentation to
receipt of ﬁrst dialysis, date of dialysis independence,
duration of dialysis, percentage of plasma cell inﬁltrate in
the bone marrow, OS and time to death.
Statistical analysis was performed using SPSS® for
Windows, version 21.0 (SPSS Inc, Chicago, IL) and Graph
Pad Prism 5.0 (GraphPad Software Inc, San Diego, CA).
Categorical variables were summarised as frequencies
and percentages. Comparisons for categorical variables
among different groups were made with the chi-square
test and Fisher’s exact test where appropriate. Con-
tinuous variables were expressed as mean and standard
deviation (SD) if the data was normally distributed or
median with range for non-normally distributed data.
Non-parametric comparisons were performed by using
the Mann-Whitney U test. Correlation analysis between
patients presenting with eGFR <15 ml/min/1.73 m2
irrespective of haemodialysis status at diagnosis and
serum FLC levels was performed with Spearman’s rank
test. In addition to reporting levels of FLC in serum that
were associated with MCN, we also examined variables
collected at presentation that correlated with renal
function recovery in patients on haemodialysis and OS.
For patients on haemodialysis, renal function recovery
was deﬁned as a sustained independence from dialysis
treatment for at least two months. Patients were followed
until death from any cause or censored on 31st December
2014, if they were still alive at this date, for survival
analysis. In order to reduce the possibility for lead-time
bias, OS for patients who achieved independence from
haemodialysis and were alive were compared with OS for
patients who were haemodialysis dependent and alive in a
landmark analysis at 3 months, 6 months, 9 months
months after presentation with a new diagnosis of MCN.
Patients who died before the landmark time were
excluded and OS for the landmark analysis was per-
formed from the landmark time to death. Outcomes in
patients with MM have progressively improved with time
due to the advances in supportive care and introduction
of novel anti-myeloma therapies. From 2008, the che-
motherapy regimens based on the proteasome inhibitor
bortezomib became the standard of care for MM and
severe AKI, and hence differences in survival were
compared between those diagnosed with MCN before
and after this time-point. All statistical tests were two
sided and a P value of <0.05 was considered as signiﬁcant.
Results
Patient demographic and disease characteristics
103 patients with incident MM, with no previous his-
tory of CKD, serum FLC level available at diagnosis and
histologically conﬁrmed MCN by renal biopsy were
included in the study. Table 1 summarises the baseline
characteristics of patients in the study. The median age at
presentation was 63 years (range 38–85), 57.3% were of
male gender, and 88.3% were white. Light chain restricted
MM (47.6%) was the predominant paraprotein type. An
involved monoclonal kappa (κ) FLC isotype was present
in 54.4% and an involved lambda (λ) FLC in 45.6% of
patients.
The median involved serum FLC level at presentation
was 7531 mg/L (range 107–114,600). Distribution of FLC
levels in serum for the entire cohort is presented in Fig. 2.
There was no signiﬁcant difference in the levels of FLC in
serum for patients presenting with involved κ FLC or
involved λ FLC isotypes (P= 0.211). Two (1.9%) patients
presented with an involved serum FLC level that was
≤500 mg/L at diagnosis; one patient was hypercalcaemic,
and the other patient had a high-normal serum calcium
level and was on a non-steroidal anti-inﬂammatory drug.
Renal characteristics at diagnosis
Sixty-nine (66.9%) patients required haemodialysis
after the diagnosis of MCN. Of these 51 patients received
extracorporeal treatment; 31 with plasma exchange (PE,
Mayo Clinic and UAB) and 21 with high-cut off hae-
modialysis (HCO-HD, UHB). The median time from
presentation to start of haemodialysis was one day (range
0–202); two patients started haemodialysis 30 days after
presentation (day 49 and day 202, respectively). There
was no signiﬁcant difference in serum FLC levels in
patients presenting with eGFR <15 ml/min/1.73 m2 at
diagnosis irrespective of haemodialysis status (median
serum FLC level in patients not requiring haemodialysis
7444 mg/L [range 575–32,294] and 8643 mg/L [range
580–114,600] for those requiring haemodialysis, P=
0.895) (Fig. 3).
Renal outcomes and patient survival
Thirty-four (33%) patients had no requirement for
haemodialysis treatment at diagnosis. For the 69 (66.9%)
patients who required haemodialysis at diagnosis, 36
(52.1%) achieved recovery of renal function. The median
duration of haemodialysis treatment was 36 days (range
10–701).
We found no signiﬁcant difference in age, eGFR, cor-
rected calcium, haemoglobin, and involved serum FLC
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level at presentation between patients who required hae-
modialysis and recovered renal function compared to
those who remained dialysis-dependent. There was no
difference in the renal recovery rate for patients who
received PE (P= 0.282) or HCO-HD compared to stan-
dard dialysis (P= 0.336).
Patients who did not require dialysis had higher hae-
moglobin concentration (median 98 g/L [range 54–129] vs
86 g/L [range 46–126] respectively, P= 0.010), and lower
involved serum FLC level (median 6724mg/L [range
107–32,294] vs 10134mg/L [range 1620–114,600],
P= 0.044) compared to those who remained dialysis-
dependent.
At the end of the follow-up period, 66 (64%) patients
had died. The median OS from diagnosis was 2.5 years
(95% CI 1.8–3.3). There was no signiﬁcant difference in
OS between patients who received haemodialysis at pre-
sentation (median 2.0 years; 95% CI 0.9–3.1) compared
to those who had no requirement for dialysis (median
3.5 years; 95% CI 1.6–5.5) (P= 0.248). This ﬁnding was
unchanged in an analysis that excluded the patient who
started haemodialysis on day 202 after the diagnosis of





Patients requiring dialysis and
recovering renal function
(n= 36)
Patients requiring dialysis and
not recovering renal function
(n= 33)
Centres
UHB 64 (62.1) 14 (41.1) 27 (75.0) 23 (69.7)
Mayo 32 (31.1) 17 (50.0) 7 (19.4) 8 (24.2)
UAB 7 (6.8) 3 (8.8) 2 (5.5) 2 (6.0)
Age (years) 63 (38–85) 64 (38–84) 60 (43–72) 65 (45–85)
Gender
Male 59 (57.3) 19 (55.9) 25 (69.4) 15 (45.4)
Female 44 (42.7) 15 (44.1) 11 (30.5) 18 (54.5)
Ethnicity
White 91 (88.3) 32 (94.1) 30 (83.3) 29 (87.8)
Non-white 12 (11.6) 2 (5.8) 6 (16.6) 4 (12.1)
Paraprotein type
Light chain restricted MM 49 (47.6) 14 (41.1) 15 (41.6) 20 (60.6)
Whole Ig MM 54 (52.4) 20 (58.8) 21 (58.3) 13 (39.3)
FLC isotype
Kappa (κ) 56 (54.4) 16 (47) 19 (52.7) 21 (63.6)
Lambda (λ) 47 (45.6) 18 (52.9) 17 (47.2) 12 (36.3)
FLC level (mg/L)
FLC level irrespective of
isotype
7531 (107–114,600) 6724 (107–32,294) 7960 (580–43,161) 10134 (1620–114,600)
κ FLC level 6965 (201–46,000) 6474 (201–32,294) 7844 (580–28,622) 9302 (1620–46,000)
λ FLC level 8220 (107–114,600) 6853 (107–20,000) 8108 (1971–43161) 12667 (1760–114,600)
Serum creatinine (μmol/L) 535 (168–2993) 349 (168–1141) 685 (329–2210) 778 (265–2993)
eGFR (ml/min/1.73 m2) 7 (1–34) 12 (3–34) 6 (2–15) 5 (1–17)
Haemoglobin (g/L) 90 (46–131) 99 (54–129) 86 (56–131) 86 (46–126)
Corrected calcium (mmol/L) 2.35 (1.65–4.25) 2.38 (1.96–4.25) 2.32 (1.65–3.27) 2.43 (1.97–4.23)
Percentage plasma cell
inﬁltrate on bone marrow
55 (1–90) 60 (1–85) 50 (10–90) 55 (20–90)
Mean ± standard deviation or median (range) reported for continuous variables and frequency (percentage) reported for categorical variables.
UHB University Hospital Birmingham, UAB University of Alabama at Birmingham, MM multiple myeloma, Ig immunoglobulin, FLC free light chain.
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MCN. Patients who received haemodialysis at diagnosis
and subsequently recovered renal function showed a sig-
niﬁcantly improved OS (median 3.3 years, 95% CI
1.6–5.0) compared to those who remained dialysis-
dependent (median 0.8 years, 95% CI 0.6–1.0)
(P < 0.0001). On performing a landmark analysis, inde-
pendence from dialysis at 3-month (P= 0.003), 6-month
(P= 0.035) and 9-month (P= 0.014) time points were
associated with improved survival whereas no such sur-
vival beneﬁt was observed beyond 12 months (P= 0.146)
(Table 2).
The median OS amongst patients who presented after
2008 was 3.8 years (95% CI 2.5–5.1) and was signiﬁcantly
better compared to those who presented before 2008
(median 1.7 years, 95% CI 0.6–2.9) (P < 0.006). We found
no statistically signiﬁcant change in the rates of renal
function recovery (P= 0.151) between those presenting
before or after 2008.
Discussion
In this multicentre study the principal ﬁndings were: (1)
the variable range of FLC levels in serum that were
observed in patients presenting with biopsy-conﬁrmed
MCN; (2) Six patients had an FLC level <1500 mg/L, the
level recommend by the IMWG for MCN; (3) two of the
103 patients presented with FLC levels ≤500mg/L, both
with precipitants for the development of cast nephro-
pathy; (4) dialysis independence within 12 months was
associated with better OS; and (5) the serum FLC level at
presentation was not associated with renal function
recovery or with patient survival.
This study is the largest analysis to date of the rela-
tionship between FLC level in serum and biopsy-
conﬁrmed MCN. To the best of our knowledge only
thirty-ﬁve studies have reported on serum FLC level in
patients with biopsy-conﬁrmed MCN9,16–46. The median
numbers of patients reported in these studies were 5
(range 1–98) and the median serum FLC levels at diag-
nosis where available were: involved κ FLC 14,100mg/L
(range 80–42,000) and involved λ FLC 4267mg/L (range
855–69,430).
Immunoassays for serum FLC have only entered wide-
spread clinical practice in the last decade and there is
limited data on the relationship between serum FLC level
and MCN. The IMWG in their recent revised diagnostic
criteria for MM included RI caused by MCN as a mye-
loma deﬁning event, where MCN was characterised by the
presence of typical histological features or an involved
Table 2 Landmark analysis of associations between haemodialysis independence and overall survival in patients with
MCN (n= 69).
HD independent HD dependent
Landmark time Pts excluded
(n)









3 month 9 35 22 3.85 25 21 1.12 0.003
6 month 17 34 21 3.85 18 15 1.73 0.035
9 month 19 32 19 4.23 18 15 1.72 0.014
12 month 25 31 18 4.23 13 10 2.93 0.146
Fig. 2 Distributions of FLC level in serum. Percentage of patients
with FLC levels in serum grouped by <500mg/L, 501–5000mg/L, and
>1500mg/L.
Fig. 3 Serum FLC levels at diagnosis. Box-plot of serum FLC levels at
diagnosis in patients presenting with eGFR <15ml/min/1.73 m2 by
dialysis status (HD, haemodialysis).
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serum FLC level above 1500 mg/L13. The IKMG research
group recommended an involved serum FLC level above
500mg/L in patients with AKI as a threshold level for
suspecting MCN and for consideration of an urgent
haemato-oncological work up14. The results in the pre-
sent study supports the IKMG threshold for MCN, as
5.8% of patients presented with a serum FLC level below
1500 mg/L; these patients would have been at risk of
misdiagnosis if using the IMWG threshold for MCN. In a
recent analysis of the myeloma IX clinical trial we found
22.7% of patients had a serum FLC level >1500mg/L at
presentation whereas 43.7% had serum FLC > 500mg/L.
In the same study, renal impairment deﬁned as an eGFR
<60ml/min/1.73 m2 was noted in 71.4% of patients with
serum FLC level above 1500 mg/L, and this was 60.6% in
patients with serum FLC levels > 500 mg/L15. Importantly
this study showed that patients could have a very high
FLC level and no RI at diagnosis. This is consistent with
experimental work which shows that each FLC has a
speciﬁc level for precipitation. Animal studies also showed
that the threshold for cast formation is lower in the pre-
sence of a co-precipitant10. The two patients with FLC
levels ≤500mg/L had co-precipitating factors.
There is great interest in improving the time to diag-
nosis and commencement of treatment for MCN. Hence,
deﬁning the serum FLC levels associated with MCN using
the above threshold is an important component of
achieving this aim. This would help by averting the need
for delays and risks associated with renal biopsy, and
consequent delay in initiation of life and organ saving
anti-myeloma treatment. In addition, knowledge of early
changes in serum FLC levels from baseline after com-
mencement of chemotherapy in patients with MCN may
also direct early changes in therapy. There is evidence that
early disease response deﬁned by a reduction in serum
FLC is associated with an increased probability of renal
recovery47.
A secondary aim of this study was to assess the asso-
ciation between serum FLC levels at presentation with
renal recovery and OS in this population of patients who
presented with severe RI. This analysis was limited by the
change in time frame over which the study was performed
and missing details of the chemotherapy regimens used
for some patients. To date there are no studies that have
reported on the relationship between serum FLC levels at
diagnosis in patients presenting with MCN and sub-
sequent renal recovery. We found that the level of serum
FLC level at presentation had no inﬂuence on whether or
not patients who required dialysis subsequently recovered
independent renal function or remained dialysis-
dependent.
There is however growing evidence that OS is improv-
ing substantially in patients with MM who require dialysis
for AKI48; this improvement may be associated with
increasing use of bortezomib-based regimens49. We did
not have sufﬁcient information on chemotherapy to per-
form an assessment of the impact of use of bortezomib,
but by time-period we found a signiﬁcantly better OS in
patients who presented after 2008, the period when bor-
tezomib came into widespread use for patients with MM
and AKI, compared to patients who presented before
2008 (P= 0.006). Treatment of MM with bortezomib-
based regimens became increasingly common after 2008
and the evidence in clinical and epidemiological studies
for patients with MM and RI supports the beneﬁts of this
treatment30,48. The lack of association with extracorporeal
removal of FLC is consistent with the major randomised
controlled trials for plasma exchange and HCO-HD.in
patients with MM and AKI46,50,51.
In conclusion, this is the largest study of the relationship
between serum FLC levels and biopsy-conﬁrmed MCN in
patients with MM. 98% of patients with MCN at diagnosis
presented with a serum FLC level > 500mg/L. Based on
the ﬁndings from this study we propose that a serum FLC
level > 500mg/L should be considered for future diag-
nostic criteria for MCN. This recommendation is
only valid for the Freelite® FLC assay (The Binding Site,
Birmingham) and validation with other FLC assays have
not been performed. Serum FLC level at diagnosis was not
associated with patient outcomes in MCN. Renal function
recovery within 12 months was associated with improved
survival in patients with MCN when compared to those
who remained dialysis-dependent, no such beneﬁt was
observed after 12 months.
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